News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EU Nations Join Forces Against Gilead Sciences, Inc. (GILD)'s "Exorbitant" Hepatitis C Drug


7/11/2014 7:16:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Paris (AFP) - France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical cost.

Sovaldi, made by US pharmaceutical firm Gilead Sciences, has shown huge potential at helping cure the liver disease but its price -- more than 50,000 euros ($68,000) for a 12-week course of treatment -- has health authorities concerned.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release
Read at News Release
Read at MedicalXpress


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES